Bispecific antibodies (anti-mPEG/anti-HER2) for active tumor targeting of docetaxel (DTX)-loaded mPEGylated nanocarriers to enhance the chemotherapeutic efficacy of HER2-overexpressing tumors

References

• Allen TM. (2002). Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2:750–63.
   PubMed Web of Science ®Google Scholar
• Allen C, Dos Santos N, Gallagher R, et al. (2002). Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Bio Sci Rep 22:225–50.
   PubMed Web of Science ®Google Scholar
• Brigger I, Dubernet C, Couvreur P. (2012). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 64:24–36.
   Web of Science ®Google Scholar
• Chabner BA, Roberts TG. Jr. (2005). Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72.
   PubMed Web of Science ®Google Scholar
• Charmainne C, Chithrani DB. (2014). Polyethylene glycol density and length affects nanoparticle uptake by cancer cells. J Nanomed Res 1:00006.
   Google Scholar
• Chen LC, Chen YC, Su CY, et al. (2016). Development and characterization of self-assembling lecithin-based mixed polymeric micelles containing quercetin in cancer treatment and an in vivo pharmacokinetic study. Int J Nanomed 11:1557–66.
   PubMed Web of Science ®Google Scholar
• Chen YC, Su CY, Jhan HJ, et al. (2015). Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int J Nanomedicine 10:7265–74.
   PubMed Web of Science ®Google Scholar
• Chuang KH, Tzou SC, Cheng TC, et al. (2010). Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA. Anal Chem 82:2355–62.
   PubMed Web of Science ®Google Scholar
• Cortese K, Howes MT, Lundmark R, et al. (2013). The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments. Mol Biol Cell 24:129–44.
   PubMed Web of Science ®Google Scholar
• Dave V, Yadav RB, Kushwaha K, et al. (2017). Lipid-polymer hybrid nanoparticles: development & statistical optimization of norfloxacin for topical drug delivery system. Bioact Mater 2:269–80.
   PubMed Web of Science ®Google Scholar
• Davis ME, Chen ZG, Shin DM. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7:771–82.
   PubMed Web of Science ®Google Scholar
• Dennison SM, Stewart SM, Stempel KC, et al. (2009). Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J Virol 83:10211–23.
   PubMed Web of Science ®Google Scholar
• Dutta D, Donaldson JG. (2012). Search for inhibitors of endocytosis: intended specificity and unintended consequences. Cell Logist 2:203–8.
   PubMedGoogle Scholar
• Gao J, Liu W, Xia Y, et al. (2011). The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32:3459–70.
   PubMed Web of Science ®Google Scholar
• Haberger M, Bomans K, Diepold K, et al. (2014). Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes. MAbs 6:327–39.
   PubMed Web of Science ®Google Scholar
• Hare JI, Lammers T, Ashford MB, et al. (2017). Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv Drug Deliv Rev 108:25–38.
   PubMed Web of Science ®Google Scholar
• Henley JR, Cao H, Mcniven MA. (1999). Participation of dynamin in the biogenesis of cytoplasmic vesicles. FASEB J 13:S243–S7.
   PubMed Web of Science ®Google Scholar
• Itoh K, Watanabe A, Funami K, et al. (2008). The clathrin-mediated endocytic pathway participates in dsRNA-induced IFN-β production. J Immunol 181:5522.
   PubMed Web of Science ®Google Scholar
• Kamaly N, Xiao Z, Valencia PM, et al. (2012). Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971–3010.
   PubMed Web of Science ®Google Scholar
• Kao CH, Wang JY, Chuang KH, et al. (2014). One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles. Biomaterials 35:9930–40.
   PubMed Web of Science ®Google Scholar
• Koo H, Huh MS, Sun IC, et al. (2011). In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res 44:1018–28.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy S, Vaiyapuri R, Zhang L, Chan JM. (2015). Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater Sci 3:923–36.
   PubMed Web of Science ®Google Scholar
• Kuhn DA, Vanhecke D, Michen B, et al. (2014). Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages. Beilstein J Nanotechnol 5:1625–36.
   PubMed Web of Science ®Google Scholar
• Li Q, Xia D, Tao J, et al. (2017). Self-assembled core-shell-type lipid-polymer hybrid nanoparticles: intracellular trafficking and relevance for oral absorption. J Pharm Sci 106:3120–30.
   PubMed Web of Science ®Google Scholar
• Macia E, Ehrlich M, Massol R, et al. (2006). Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell 10:839–50.
   PubMed Web of Science ®Google Scholar
• Manjappa AS, Chaudhari KR, Venkataraju MP, et al. (2011). Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 150:2–22.
   PubMed Web of Science ®Google Scholar
• Mikhalin AA, Evdokimov NM, Frolova LV, et al. (2014). Lipophilic prodrug conjugates allow facile and rapid synthesis of high loading capacity liposomes without the need for post-assembly purification. J Liposome Res 25:1–29.
   PubMed Web of Science ®Google Scholar
• Nicolas J, Mura S, Brambilla D, et al. (2013). Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 42:1147–235.
   PubMed Web of Science ®Google Scholar
• Peer D, Karp JM, Hong S, et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech 2:751–60.
   PubMed Web of Science ®Google Scholar
• Perez HL, Cardarelli PM, Deshpande S, et al. (2014). Antibody-drug conjugates: current status and future directions. Drug Discov Today 19:869–81.
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Kishi K, Hirota S, Sonobe T. (2003). Effect of polyethyleneglycol (PEG) chain on cell uptake of PEG-modified liposomes. J Liposome Res 13:157–72.
   PubMed Web of Science ®Google Scholar
• Sahay G, Alakhova DY, Kabanov AV. (2010). Endocytosis of nanomedicines. J Control Release 145:182–95.
   PubMed Web of Science ®Google Scholar
• Sheu MT, Wu CY, Su CY, Ho HO. (2017). Determination of total and unbound docetaxel in plasma by ultrafiltration and UPLC-MS/MS: application to pharmacokinetic studies. Sci Rep 7:14609.
   PubMed Web of Science ®Google Scholar
• Su CY, Liu JJ, Ho YS, et al. (2018). Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (LsbMDDs) for improving the therapeutic efficacy and reducing systemic toxicity. Eur J Pharm Biopharm 123:9–19.
   PubMed Web of Science ®Google Scholar
• Tenzer S, Docter D, Kuharev J, et al. (2013). Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol 8:772.
   PubMed Web of Science ®Google Scholar
• Tietze S, Schau I, Michen S, et al. (2017). A poly(propyleneimine) dendrimer-based polyplex-system for single-chain antibody-mediated targeted delivery and cellular uptake of SiRNA. Small 13: 1700072.
   Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. (2012). Nanoparticle delivery of cancer drugs. Annu Rev Med 63:185–98.
   PubMed Web of Science ®Google Scholar
• Zhao F, Zhao Y, Liu Y, et al. (2011). Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 7:1322–37.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Meng F, Deng C, Zhong Z. (2014). Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 15:1955–69.
   PubMed Web of Science ®Google Scholar
• Zhu X, Xu Y, Solis LM, et al. (2015). Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci USA 112:7779–84.
   PubMed Web of Science ®Google Scholar